Third Harmonic Bio Investor Relations Material

Third Harmonic Bio Inc., operating under the ticker THRD, is a clinical-stage biopharmaceutical company dedicated to developing therapies for inflammatory diseases affecting the skin, respiratory system, and gastrointestinal tract. The company is actively working on novel treatments and focuses on KIT inhibition, a key regulatory mechanism in mast cell function, which plays a substantial role in inflammatory responses across these conditions. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.